Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most （clusters of differentiation）CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells^[1]^[2].

References:

[1]. L Franco, et al. The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes. FASEB J. 1998 Nov;12(14):1507-20. [Content Brief]

[2]. Kumi Oshima, et al. SHPS-1, a multifunctional transmembrane glycoprotein. FEBS Lett. 2002 May 22;519(1-3):1-7. [Content Brief]

Transmembrane Glycoprotein Related Products (144):

By Effects:	Inhibitors (86) Ligands (2) Agonists (3) Antagonists (3) Activators (6) Modulators (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P99329

Vadastuximab		99.23%
Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine.

HY-128111

ASN02563583	Activator	99.21%
ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC₅₀ value of 0.64 nM in [₃₅S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases.

HY-P9983

Lintuzumab	Inhibitor	98.09%
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice.

HY-144399

CD33 splicing modulator 1	Inhibitor	99.55%
CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease.

HY-P2284

AD 01	Ligand
AD 01, a 24 amino acid peptide of FKBPL (FK506-binding protein like), possesses potent anti-angiogenic activity. AD 01 bind to the CD44 receptor and inhibit tumour cell migration in a CD44 dependant manner.

HY-P990294

Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)	Inhibitor
Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD106/VCAM-1.

HY-P99266

Zanolimumab		99.21%
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma.

HY-P99566

Tenatumomab
Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach.

HY-113667

ASN04885796	Activator	99.61%
ASN04885796 (compound IV) is an GPR17 activator with an EC₅₀ of 2.27 nM for GPR17 induced GTPγS binding. ASN04885796 has neuroprotective property and can be used for research of neurological diseases.

HY-P99958

Vixtimotamab	Inhibitor
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML).

HY-P990859

Anti-CD44 Antibody (Hermes-1)
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a, κ chimeric antibody, targeting to human CD44. The recommend isotype control of Anti-CD44 Antibody (Hermes-1): Rat IgG2a kappa, Isotype Control (HY-P990679).

HY-P990032

Belrestotug	Inhibitor
Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity.

HY-137605

WSF1-IN-1	Inhibitor	99.91%
WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC₅₀ values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively.

HY-P990351

Anti-CD34 Antibody	Inhibitor	99.90%
The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990259

Anti-Mouse CD96 Antibody (3.3)	Inhibitor
Anti-Mouse CD96 Antibody (3.3) is a rat-derived IgG1, λ type antibody inhibitor, targeting to mouse CD96.

HY-W081348

1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one		99.54%
1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one (Compound 2) has antiprion activity in ScN2a and F3 cells with IC₅₀ values of 13 nM and 25 nM, respectively.

HY-113481

Prostaglandin E3	Inhibitor	≥99.0%
Prostaglandin E3 is an eicosanoid derived from eicosapentaenoic acid. Prostaglandin E3 inhibits polarization towards M1 but promotes polarization of M2a macrophages. Prostaglandin E3 shows anti-inflammatory and anti-tumor activity.

HY-P990607

Indatuximab	Inhibitor	98.04%
Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990792

Anti-Mouse CD4 Antibody (GK1.5)
Anti-Mouse CD4 Antibody (GK1.5) is a kind of rat IgG2b kappa in vivo mouse antibody, targeting to CD4. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-110104

8MDP	Inhibitor
8MDP is a potent equilibrative nucleoside transporter 1 (ENT1) inhibitor with an IC₅₀ of 0.43 nM. 8MDP inhibits hENT1 and hENT2 uptake of [H³] uridine by K562 cells and K15NTD cells.

Name
Email *

	Sorry, but the email address you supplied was invalid.